A Phase 3 interventional study of Atogepant and Placebo in Episodic Migraine, sponsored by Allergan. Completed at 138 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-09.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 15 in phase 3, and was the 3rd registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 910 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 7th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2018, is one of 30 in phase 3, and was the 24th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo-matching atogepant tablets orally once daily for 12 weeks.
Drug: Placebo
Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
Drug: Atogepant · Drug: Placebo
Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
Drug: Atogepant · Drug: Placebo
Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
Drug: Atogepant · Drug: Placebo
Atogepant tablet
Placebo-matching atogepant tablets
Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days was defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. A Mixed-effects model for repeated measures (MMRM) was used for analysis.
Time frame: Baseline (Day -28 to Day -1) to Week 12
Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period
Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache qualified by duration or acute symptomatic medication use. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. MMRM was used for analysis.
Time frame: Baseline (Day-28 to Day -1) to Week 12
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period
Participants recorded allowed medication(s) to treat an acute migraine in the daily diary. The monthly (4-week) acute medication use days was defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of acute medication use days during the last 28 days of the Baseline phase, from Day -28 to -1. A negative change from Baseline indicates improvement. MMRM was used for the analysis.
Time frame: Baseline (Day-28 to Day -1) to Week 12
Percentage of Participants With at Least a 50% Reduction (Improvement) in 3-month Average of Monthly Migraine Days
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. Each 4-week period was averaged.
Time frame: Baseline (Day -28 to Day -1) to Week 12
Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12
MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into three domains: role function-restrictive (questions 1-7, score range 7 to 42) assesses how migraines limit one's daily social and work-related activities; role function-preventive (questions 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the emotional function (questions 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale where 1=none of the time and 6=all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores from Baseline indicate better quality of life. MMRM was used for the analysis.
Time frame: Baseline (Day 1) to Week 12
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine-Diary (AIM-D) Across the 12-Week Treatment Period
The AIM-D is a 9-item PRO measure that assesses the impact of migraine on the performance of daily activities and physical impairment using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). Baseline was defined as the monthly (averaged for a month) performance of daily activities domain score during the last 28 days of the Baseline period from Day -28 to -1. MMRM was used for the analysis.
Time frame: Baseline (Day -28 to Day -1) to Week 12
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the Activity Impairment in Migraine- Diary (AIM-D) Across the 12-Week Treatment Period
The AIM-D is a 9-item PRO measure that assesses the impact of migraine on the performance of daily activities and physical impairment using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). Baseline was defined as the monthly (averaged for a month) physical impairment domain score during the last 28 days of the Baseline period from Day -28 to -1. MMRM was used for the analysis.
Time frame: Baseline (Day -28 to Day -1) to Week 12
| Milestone | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Started | 223 | 222 | 230 | 235 |
| Treated: safety population | 222 | 221 | 228 | 231 |
| Completed | 201 | 193 | 207 | 204 |
| Not completed | 22 | 29 | 23 | 31 |
| Withdrew: Adverse event | 6 | 9 | 4 | 6 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 9 | 8 | 10 |
| Withdrew: Lost to follow-up | 3 | 3 | 4 | 5 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 4 | 5 | 7 | 8 |
| Withdrew: Reason not specified | 0 | 2 | 0 | 1 |
| Milestone | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Started | 46 | 54 | 38 | 45 |
| Completed | 41 | 49 | 32 | 36 |
| Not completed | 5 | 5 | 6 | 9 |
| Withdrew: Withdrawal by subject | 5 | 3 | 4 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 3 |
| Withdrew: Protocol deviation | 0 | 1 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 1 | 1 |
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days was defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. A Mixed-effects model for repeated measures (MMRM) was used for analysis.
| migraine days per month | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period | -2.48 ± 0.210 | -3.69 ± 0.210 | -3.86 ± 0.206 | -4.20 ± 0.206 |
Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache qualified by duration or acute symptomatic medication use. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. MMRM was used for analysis.
| headache days per month | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period | -2.52 ± 0.225 | -3.94 ± 0.225 | -4.04 ± 0.221 | -4.23 ± 0.221 |
Participants recorded allowed medication(s) to treat an acute migraine in the daily diary. The monthly (4-week) acute medication use days was defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of acute medication use days during the last 28 days of the Baseline phase, from Day -28 to -1. A negative change from Baseline indicates improvement. MMRM was used for the analysis.
| acute medication use days per month | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period | -2.35 ± 0.184 | -3.66 ± 0.183 | -3.68 ± 0.180 | -3.85 ± 0.180 |
Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. Each 4-week period was averaged.
| percentage of participants | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Percentage of Participants With at Least a 50% Reduction (Improvement) in 3-month Average of Monthly Migraine Days | 29.0 | 55.6 | 58.7 | 60.8 |
MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into three domains: role function-restrictive (questions 1-7, score range 7 to 42) assesses how migraines limit one's daily social and work-related activities; role function-preventive (questions 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the emotional function (questions 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale where 1=none of the time and 6=all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores from Baseline indicate better quality of life. MMRM was used for the analysis.
| score on a scale | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12 | 20.45 ± 1.617 | 30.35 ± 1.639 | 30.53 ± 1.593 | 31.25 ± 1.591 |
The AIM-D is a 9-item PRO measure that assesses the impact of migraine on the performance of daily activities and physical impairment using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). Baseline was defined as the monthly (averaged for a month) performance of daily activities domain score during the last 28 days of the Baseline period from Day -28 to -1. MMRM was used for the analysis.
| score on a scale | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine-Diary (AIM-D) Across the 12-Week Treatment Period | -6.09 ± 0.504 | -7.28 ± 0.500 | -8.63 ± 0.502 | -9.41 ± 0.504 |
The AIM-D is a 9-item PRO measure that assesses the impact of migraine on the performance of daily activities and physical impairment using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). Baseline was defined as the monthly (averaged for a month) physical impairment domain score during the last 28 days of the Baseline period from Day -28 to -1. MMRM was used for the analysis.
| score on a scale | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Physical Impairment Domain Score of the Activity Impairment in Migraine- Diary (AIM-D) Across the 12-Week Treatment Period | -4.03 ± 0.439 | -5.11 ± 0.436 | -6.02 ± 0.438 | -6.49 ± 0.439 |
Collected over From first dose of study drug through end of study (Up to 16 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/223 (0%) | 2/222 (0.9%) | 15/222 (6.8%) |
| Atogepant 10 mg | 0/222 (0%) | 2/221 (0.9%) | 34/221 (15.4%) |
| Atogepant 30 mg | 0/230 (0%) | 0/228 (0%) | 37/228 (16.2%) |
| Atogepant 60 mg | 0/235 (0%) | 0/231 (0%) | 32/231 (13.9%) |
| Event | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Optic neuritisNervous system disorders | 0/222 | 1/221 | 0/228 | 0/231 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/222 | 1/221 | 0/228 | 0/231 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/222 | 0/221 | 0/228 | 0/231 |
| Brain injuryNervous system disorders | 1/222 | 0/221 | 0/228 | 0/231 |
| Negative pressure pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 1/222 | 0/221 | 0/228 | 0/231 |
| Event | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/222 | 17/221 | 16/228 | 16/231 |
| NauseaGastrointestinal disorders | 4/222 | 11/221 | 10/228 | 14/231 |
| Upper respiratory tract infectionInfections and infestations | 10/222 | 9/221 | 13/228 | 9/231 |
Safety Population included all participants who received at least 1 dose of study intervention.
| Age, Continuous(years) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 40.3 ± 12.81 | 41.4 ± 12.05 | 42.1 ± 11.68 | 42.5 ± 12.41 | 41.6 ± 12.25 |
| Sex: Female, Male(Participants) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Female | 198 | 200 | 204 | 199 | 801 |
| Male | 24 | 21 | 24 | 32 | 101 |
| Race (NIH/OMB)(Participants) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 1 | 3 |
| Asian | 2 | 2 | 1 | 7 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 24 | 34 | 38 | 28 | 124 |
| White | 194 | 181 | 185 | 192 | 752 |
| More than one race | 2 | 3 | 3 | 2 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Hispanic | 23 | 21 | 19 | 14 | 77 |
| Non-Hispanic | 199 | 200 | 209 | 217 | 825 |
| Monthly Migraine Days(migraine days per month) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 7.5 ± 2.39 | 7.5 ± 2.46 | 7.9 ± 2.32 | 7.8 ± 2.31 | 7.6 ± 2.37 |
| Monthly Headache Days(headache days per month) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 8.4 ± 2.55 | 8.4 ± 2.75 | 8.8 ± 2.62 | 9.0 ± 2.56 | 8.7 ± 2.63 |
| Monthly Acute Medication Use(acute medication use days per month) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 6.5 ± 3.15 | 6.6 ± 2.99 | 6.7 ± 3.02 | 6.9 ± 3.17 | 6.7 ± 3.08 |
| MSQ v2.1 Role Function-Restrictive Domain Score(score on a scale) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 46.8 ± 19.67 | 44.9 ± 21.37 | 44.0 ± 19.61 | 46.8 ± 20.36 | 45.6 ± 20.26 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 138 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in Jun 2020, 18 months.
Results were first posted in Jul 2021, 1 year after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 18 months is close to that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant